Immunohistological staining of skin from normal donors and bone marr-w
molecules, endothelial leucocyte adhesion molecule-I (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1). In normal skin ELAM-1 staining was restricted to a variable but generally small number of endothelial cells which were significantly increased in graft-versus-host disease (GvHD), but only when the fully developed histological picture of epidermal basal damage and leucocytic infiltration was present. All other biopsy specimens from marrow recipients taken before or after transplantation were similar to those of normal controls even in the presence of a clinical rash consistent with early GvHD. Although VCAM-1 positivity was seen on a few endothelial cells in normal skin, staining was mainly observed on dermal dendritic cells surrounding blood vessels and adnexal structures. In specimens with histological evidence of GvHD, positive perivascular dendritic cells were increased and were accompanied by the appearance of large numbers of similar cells dispersed throughout the upper dermis. Biopsy specimens from marrow recipients before and after transplantation resembled those from normal donors except for the presence of a rash after transplantation when some specimens, which lacked the leucocytic infiltrate diagnostic of GvHD, showed an increase in VCAM-1 positive cells, particularly in the upper dermis.
The identification of these cells may therefore be useful in diagnosing early
GvHD.
Acute cutaneous graft-versus-host disease (GvHD) is characterised by lymphocytic infiltration of the upper dermis and lower epidermis, and epidermal basal keratinocyte vacuolation, and necrosis.' Similar epidermal changes may be produced by cytotoxic drugs and irradiation given before transplantation,2 and are insufficient evidence on which to base a histological diagnosis of GvHD in the absence of a mononuclear cell infiltrate.3 In previous studies undertaken in our laboratory we found that biopsy specimens from many patients with rashes who had or subsequently developed strong clinical evidence of GvHD lacked the diagnostic leucocytic infiltrate, especially if taken soon after the onset of the rash.3 In some patients with these "negative" specimens HLA-DR expression was increased on epidermal keratinocytes and was strongly associated with the subsequent development of systemic GvHD.4 As cultured keratinocytes can be stimulated to synthesise HLA-DR antigens by the addition of cytokines, we suggested that HLA-DR expression on keratinocytes in early GvHD may follow cytokine release in the dermis, consequent on the interaction between recipient dermal cells (possibly in the vascular complex) and incoming donor lymphocytes.
In keratinocyte cultures stimulated this way, HLA-DR expression is preceded by synthesis of the intercellular adhesion molecule ICAM-1 (CD54),5 and in a recent histological study we showed increased ICAM-1 staining of keratinocytes in GvHD. 6 Although there was a strong positive correlation with HLA-DR positivity, we could find no evidence of increases in biopsy specimens without detectable leucocytic infiltration.
In this study we investigated the expression of two blood vessel associated leucocyte adhesion molecules, endothelial leucocyte adhesion molecule-I (ELAM-1)7 and vascular cell adhesion molecule-I (VCAM-1)8 in the skin of allogeneic marrow recipients to elucidate the possible role for adhesion molecules in acute GvHD and to investigate their possible usefulness in the early diagnosis of this condition.
Methods
Twenty five 3 mm punch biopsy specimens of skin were obtained from 24 allogeneic bone marrow recipients (15 males and nine females) between days 7 and 43 after transplantation. The underlying disease was acute myeloid leukaemia in 13 cases, chronic granulocytic leukaemia in five, acute lymphoblastic leukaemia in three, aplastic anaemia in one, myelodysplasia in one and myelofibrosis in one. The mean age at transplantation was 28 years (range 13-44). Before transplantation conditioning regimens included combinations of total body irradiation, melphalan, cyclophosphamide and busulphan according to the primary diagnosis. All patients received cyclosporin A alone or cyclosporin A plus methotrexate as prophylaxis against GvHD.
Fifteen biopsy specimens were from patients Vessel associated adhesion molecules in nornial skin and GvHD who had a macular erythematous rash mainly affecting the palms, soles, malar area and trunk, but occasionally this was more widespread affecting the back and limbs. Specimens were taken from these sites. Two groups were selected according to their histological and immunohistological appearances: (1) those specimens exhibiting unequivocal histological evidence of GvHD with leucocytic infiltration of the upper dermis and lower epidermis; and (2) biopsy specimens lacking a leucocytic infiltrate but exhibiting keratinocyte HLA-DR positivity. Ten specimens were from patients with no evidence of a rash at similar times after transplantation.
Control biopsy specimens were obtained from five normal bone marrow donors (three men and two women) of mean age 35 years (range 29-41), from the posterior iliac crest at the time of bone marrow harvest and also from five patients (three men and two women) before transplantation from the site of a Hickman line insertion. Informed consent was obtained.
The skin biopsy specimens were immediately divided in two. One half was snap frozen in liquid nitrogen, the other formalin fixed and paraffin wax embedded for histological examination.
Cryostat sections of 5 Mm were fixed in formol calcium and chloroform acetone and immunolabelled by the alkaline phosphataseantialkaline phosphatase (APAAP) method using the following monoclonal antibodies: 1 2B6 against ELAM-1; 1 4C3 against VCAM-1, both of IgGl isotype,9 and AMD-RPA-1 (Leuk 19), IgG2b isotype, against human monocyte/macrophages (Silenus, Australia through Laboratory Impex Ltd, Middlesex). Polyclonal rabbit antibodies to CD3 and factor VIII related antigen and the monoclonal antibody to monocyte/macrophages EBMI 1 (CD68) were obtained from Dako Ltd, and HLA-DR antibody L243 from Becton-Dickinson.
The number of ELAM-1 positive vascular endothelial cells was counted and expressed as cells per mm length of epidermis. VCAM-1 positive cells in the dermal vascular complex and free within the upper dermis were counted separately and also expressed as cells per mm length of epidermis. Epidermal lengths were measured using a Leitz Orthoplan Drawing Tube attached to a Laborlux microscope to project an image on to a piece of paper. The tracing of the contour of the granular layer was measured using an opisometer.
Histological appearances fell into three categories3: (1) GvHD, where there was epidermal basal damage associated with leucocytic infiltration of the upper dermis and lower epidermis; (2) epidermal basal abnormalities when there was evidence of epidermal basal damage but no lymphocytic infiltrate; and (3) normal.
In several cases of normal skin and GvHD immunofluorescence studies were undertaken.
Cryostat sections (5 pm) were fixed in acetone for 10 minutes. Sections were incubated with the antibodies or the conjugates for 30 minutes to one hour at room temperature. Phosphate buffered saline 0 1M (pH 7 4) was used for the antibody dilutions and washings.
For single labelling with the mouse monoclonal antibodies, sections were incubated with 1-2B6 or 1-4C3 diluted 1 in 100 followed by biotinylated horse anti-mouse IgG (1 in 100) (Vector Laboratories, Peterborough) and finally with streptavidin fluorescene (1 in 50).
Rabbit anti-CD3 (1 in 60) and anti-factor VIII related antigen (1 in 100) were followed by fluorescein-conjugated donkey anti-rabbit Ig (1 in 50).
Double labelling was performed by incubating the tissue sections with a combination of 1 4C3 and either anti-CD3 or anti-factor VIII related antigen at their optimum dilutions, followed by biotinylated horse anti-mouse IgG, and finally with a mixture of streptavidin Nonomura et al showed increased lymphocyte adhesion to hepatic vascular endothelium after bone marrow transplantation which paralleled the severity of portal tract infiltrates.'2 Lymphocytes from rats with early acute GvHD have been reported to show antigen specific injury to cultured endothelial cells.'3
Lymphocytic infiltration into tissues is preceded by their adhesion to vascular endothelium. This lymphocyte endothelial interaction is regulated by various adhesion molecules whose expression may be modified by local cytokine release.'4 ELAM-1 is a member of the selectin family of adhesion molecules. Its expression is increased temporarily on cultured endothelial cells by the addition of IL-la, IL-1IB, or tumour necrosis factor, with peak expression at four to six hours, diminishing noticeably at 24 hours. In human skin in vivo, however, the time sequence for ELAM-1 expressiojn has been shown to be longer and may persist for days after the onset of inflammation. 5 16 In normal skin we found ELAM-1 positivity on a variable and generally small number of endothelial cells with significant increases after transplantation only when there was unequivocal histological evidence of GvHD. No increase was seen in patients with only clinical evidence of the disease who lacked demonstrable cutaneous leucocytic infiltration, even in the presence of increased keratinocyte HLA-DR staining. The association between leucocytic infiltration and endothelial ELAM-1 expression in GvHD is not entirely clear from the present study. It is possible, however, that increases in ELAM-1 precede leucocytic infiltration and are important in allowing mononuclear cells to pass from the blood to the dermis. Our failure to show endothelial ELAM-1 positivity without (and presumably before) leucocytic infiltration could be explained by a short time interval between the two events, or the relative insensitivity of immunohistology in detecting small but pathologically important increases in the adhesion molecule. Alternatively, mononuclear cell traffic into the dermis at early time points in the evolution of GvHD may not be critically dependent on this adhesion molecule.
Even in GvHD, not all endothelial cells exhibited ELAM-1 positivity, but a lack of suitable markers prevented us from determining the precise nature of the positive and negative cells. The morphological features of the positive vessels suggested that they were blood rather than lymphatic in type. The continuous, rather than patchy, positivity in GvHD would be in keeping with a functional zone of dermal vessels concerned with regulat- Interactions between the VCAM-1 + dermal "dendrocytes" and donor T cells could be important in the pathogenesis of tissue damage in acute cutaneous GvHD and, as suggested above for VCAM-1 + perivascular cells, could involve antigen presentation. In this context it would be interesting to determine the rate at which recipient cells of each of these types are replaced by those of donor origin. Further studies are under way to investigate this.
The increase in VCAM-1 positive cells in biopsy specimens without detectable lymphocytic infiltration, taken soon after the onset of rash, raises the possibility of a role for this antibody in diagnosing early GvHD. Enumerating increases in perivascular cells would be time-consuming and largely meaningless unless counts before transplantation were available, but positive cells dispersed free in the dermis would be much easier to evaluate as they were almost entirely undetectable in the control biopsy specimens from transplant recipients. As some patients with early GvHD lack lymphocytic infiltration and keratinocyte HLA-DR positivity4 it would be of interest to determine whether any ofthem show significant increases in free dermal VCAM-1 + cells. A detailed prospective study is currently being undertaken to evaluate antibodies to VCAM-1 and other molecules in predicting clinical outcome in patients with rashes after transplantation. 
